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Article Information  ABSTRACT 
Received:  4th September 2020  A transdermal patch is a medicated adhesive patch that is applied to the skin and used to deliver a 
particular amount of medication into the bloodstream through the skin. It aids in the recovery of an 
injured bodily part. The transdermal drug delivery system (TDDS) provides an alternative safe means 
of drug delivery to previous intrusive techniques. In the past, topically applied lotions and ointments 
were the most commonly utilised systems for dermatological issues. The fact that some of these 
formulations cause systemic side effects indicates that they are absorbed through the skin. All topically 
applied medication formulations intended to transport the active ingredient into the general circulation 
are included in the transdermal delivery system.  
To overcome the skin's formidable barrier to topical medication administration, several substances have 
been utilised. Because of their unique qualities, such as improved bioavailability, regulated 
pharmaceutical release, and improved patient compliance, TDDS have recently gained increased 
attention. The current review focuses on the various advancements in transdermal drug delivery, as well 
as the various available methods for preparing transdermal patches, characterization and assessment 
tools for transdermal patch preparation, patents, transdermal compound clinical trials, and drug 
approved and future applications of transdermal drug delivery systems. As a result, in recent years, the 
Transdermal Drug Delivery System has received a lot of attention.  
Revised: 28th March 2021 












The self-contained discrete dosage forms that, when applied to 
undamaged skin, transport the drug(s) via the skin at a controlled 
rate to the systemic circulation are known as transdermal 
therapeutic systems [1]. The most common means of 
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administering most medications is through conventional dosage 
forms, which are primarily taken orally. However, the 
disadvantages of traditional dosage forms are that they 
frequently create substantial range changes in plasma drug 
concentrations, resulting in either unwanted toxicity or poor 
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efficacy. Not only that, but there are also additional issues to 
consider, such as repeated dosing and inconsistent absorption. 
As a result, the concept of a controlled medication delivery 
system or therapeutic system was born [2].  
 
The human body's skin is one of the most vast and easily 
accessible organs. It has a surface area of roughly 2m2 (or 
3000inch2) and gets around one-third of the blood that circulates 
through an ordinary adult's body. Only a few milimeters in 
thickness (2.970.28 mm). The skin keeps the underlying blood 
circulation system and vital organs safe from the elements. It 
acts as a barrier against physical and chemical attacks, as well as 
protecting the body from microorganism invasion [3]. 
 
ADVANTAGES & DISADVANTAGES OF TRANSDERMAL 
DRUG DELIVERY [4,5,6,7] 
Compared to other traditional techniques, the transdermal 
system has some significant advantages 
 Because the duration of effect is greater, the frequency of 
dose is reduced. 
 Drugs that require regular doses are more convenient to 
deliver. 
 Aids in the improvement of bioavailability. 
 Controls the plasma level uniformity. 
 The drug administration can be stopped by simply removing 
the patch from the skin. 
 With a non-invasive, painless, and uncomplicated 
application, you may be confident in patient compliance and 
comfort. 
 
Some of the greatest disadvantages of transdermal drug delivery 
are: 
1. There is a small chance of local irritation at the application 
site. 
2. The medicine, the adhesive, or any excipients in the patch 
formulation can produce erythema, irritation, and local edoema. 
 
METHODS OF PREPARATION OF TRANSDERMAL 
PATCH [8] 
1. Asymmetric TPX membrane method. 
2. Circular Teflon mould method. 
3. Mercury substrate method. 
4. By using “IPM membranes” method. 
5. By using “EVAC membranes” method. 
6. Preparation of TDDS by using proliposomes. 
7. By using free film method. 
1. Asymmetric TPX membrane method 
The backing membrane for a prototype patch will be a heat 
sealable polyester sheet (type 1009, 3m) with a 1cm diameter 
concave. The drug sample is dispensed into the concave 
membrane, which is subsequently sealed with an adhesive and 
covered by an asymmetric TPX poly (4-methyl-1-pentene) 
membrane. The dry/wet inversion procedure is used to make 
them. To make a polymer solution, TPX is dissolved in a mixture 
of solvent (cyclohexane) and non solvent ingredients at 60°C. 
The polymer solution is maintained at 40°C for 24 hours before 
being cast on a glass plate with a Gardner knife to a pre-set 
thickness. After that, the casting film is evaporated at 50°C for 
30 seconds, and the glass plate is immediately immersed in the 
coagulation bath [at 25°C]. The membrane can be removed after 
10 minutes of immersion and dried in a circulation oven at 50°C 
for 12 hours [9]. 
 
2. Circular Teflon method  
In an organic solvent, solutions containing polymers in various 
ratios are utilised. The amount of medicine calculated is 
dissolved in half the amount of the same organic solvent. 
Enhancers are dissolved in the other half of the organic solvent 
and then added in various concentrations. As a plasticizer, di-
Nbutyl phthalate is added to the drug polymer solution. The 
entire mixture must be stirred for 12 hours before being placed 
into a circular Teflon mould. In a laminar flow hood model with 
an air speed of 0.5 m/s, the moulds should be positioned on a 
levelled surface and covered with an inverted funnel to manage 
solvent vaporisation. After 24 hours, the solvent is allowed to 
evaporate. To eliminate ageing effects, the dried films must be 
held for another 24 hours at 250.5°C in a desiccator containing 
silica gel before being evaluated. Within one week of their 
preparation, the type films must be reviewed. [10]. 
 
3. Mercury substrate method  
The medication, along with the plasticizer, is dissolved in a 
polymer solution. It is then stirred for 10 to 15 minutes to achieve 
a homogeneous dispersion before being poured into a levelled 
mercury surface and covered with an inverted funnel to prevent 
solvent evaporation (Wiechers 1992). Rathore et al. looked at 
using ethyl cellulose and cellulose acetate polymer to make 
terbutaline sulphate patches with a transdermal matrix. The 
terbutaline sulphate transdermal patches were made using a 
mercury substrate and a solvent casting process. Various 
polymeric terbutaline sulphate transdermal patches were 
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produced in the current study. A permeability enhancer's effect 
on drug permeability from cellulose acetate and ethyl cellulose 
patches was studied. The polymeric combinations were capable 
of creating good films, and the casting technique on mercury 
substrate resulted in good films. Using Eudragit RL 100, 
Eudragit RS 100, Polyvinyl pyrollidone (PVP) as polymers, 
glycerol and propylene glycol as plasticizers, and Span 80 as a 
permeation enhancer, Patel et al. developed transdermal patches 
containing glibenclamide (1.06 percent w/v, i.e. 13.5 mg/cm2). 
At the end of 24 hours, the formulation including Eudragit RL 
100 and propylene glycol as a plasticizer had 98.02 percent 
complete and sustained release [11]. 
 
4. By using “IPM membranes” method  
The drug is mixed with water and propylene glycol containing 
carbomer 940 polymers and whirled for 12 hours in a magnetic 
stirrer. With the addition of triethanolamine, the dispersion will 
be neutralised and viscous. If the drug's solubility in aqueous 
solution is poor, buffer pH 7.4 can be employed to make a 
solution gel. The gel that has been created will be integrated into 
the IPM membrane [12]. 
 
5. Preparation of TDDS by using proliposomes   
A film deposition method and a carrier method are used to create 
the proliposomes. Lecithin with the ratio of 0.1:2.0 can be used 
as an improved version of the prior reference drug. 5 mg of 
mannitol powder is placed in a 100 ml round bottom flask that 
is kept at 60-70°C and spun at 80-90 rpm for 30 minutes while 
vacuum drying the mannitol. After drying, the water bath's 
temperature is set at 20-30°C. At 37°C, a 0.5ml aliquot of the 
organic solution is placed in the round bottomed flask, and after 
complete drying, additional 0.5ml aliquots of the solution are 
added. The drug-loaded mannitol powders (proliposomes) are 
placed in a desiccator overnight and sieved through a 100 grit 
sieve after the final loading. The powder is collected and placed 
in a glass bottle to be stored at a low temperature until 
characterisation [13,14]. 
 
6. By using free film method 
Casting on a mercury surface produces a free cellulose acetate 
film. Chloroform is used to make a 2 percent w/w polymer 
solution. Plasticizers are used at a 40 percent weight-to-weight 
ratio in the polymer. Five ml of polymer solution was placed in 
a glass ring that was placed over the mercury surface in a glass 
petri dish. An inverted funnel was placed over the petridish to 
control the rate of solvent evaporation. Observing the mercury 
surface after the solvent has completely evaporated reveals the 
lm creation. The dried lm will be separated and stored in 
desiccators between wax paper sheets until needed. By varying 
the volume of the polymer solution, free films of various 
thicknesses can be created [15]. 
 
CONCLUSION  
A lot of progress has been achieved in the field of transdermal 
patches. The transdermal medicine delivery system has piqued 
the curiosity of many academics due to its multiple benefits. To 
improve transdermal medication distribution, a variety of 
techniques have been used, including chemicals, electric fields, 
and ultrasound These advancements have made transdermal 
medication delivery a viable option for systemic drug 
administration. In the last two decades, there has been a 
tremendous surge in scientific interest in this field. Several 
studies have been conducted to safely breach the skin's barrier 
function, allowing therapeutic amounts of medication to be 
administered. Studies using solution or suspension formulations, 
on the other hand, have a restricted application potential. 
Transdermal devices should be designed with the system's 
functional and relevant characteristics in mind. Through a 
greater understanding of the physicochemical qualities of the 
medication, the physiology of skin, the mechanism of action of 
enhancers, and the interaction between formulation components, 
future study should be able to ensure improved delivery. 
Furthermore, a wider range of compounds could be addressed in 
the transdermal delivery arena with improved device design. 
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